A clinical trial is currently being conducted in the United States to assess a drug that could potentially prolong the lifespan of dogs.

Called the STAY trial, this study is spearheaded by Loyal, an animal health company based in San Francisco.

This double-blind, placebo-controlled trial involves a minimum of one thousand senior dogs, with the aim of obtaining approval from the U.S. Food and Drug Administration (FDA) based on the results.

The trial follows promising preclinical and pilot studies.

As explained by Alex Robb, medical director at Goodheart Animal Health Center in Colorado, the participating dogs will receive daily doses of the drug over a four-year period, accompanied by regular clinical evaluations.

Researchers will assess whether the drug has a noticeable effect on longevity upon the study's completion.

To be eligible for the trial, dogs must be at least ten years old and weigh a minimum of fourteen pounds.

Owners must agree to transfer their pet's primary care to a study clinic involved in the trial and commit to multiple veterinary visits throughout the four years.

The initial year requires six visits, followed by two visits each year thereafter.

The study aims to explore factors contributing to canine aging, such as their higher metabolic rate compared to humans.

While veterinary advancements have enhanced healthcare for dogs, their overall lifespan has not increased proportionally to human lifespans.

Loyal intends to use the data gathered to apply for conditional FDA approval of the drug by the end of the year.

Recruitment for the study is currently ongoing at various clinics nationwide.